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Abstract 
In this study it was investigated whether long-circulating amphotericin B (AMB) containing liposomes could be prepared by 
incorporation f polyethylene glycol (1900) derivatized distearoylphosphatidylethanolamine (PEG-DSPE), and whether the 
incorporation f PEG-DSPE affected toxicity and biodistribution f the preparation i  mice. Toxicity of two formulations of
liposomes containing both PEG-DSPE and AMB (PEG-AMB-LIP, types 1 and 2) was compared with that of AMB-liposomes 
without PEG-DSPE (AMB-LIP) as well as that of MB-deoxycholate (AMB-DOC). The maximum tolerated osage (MTD) 
of AMB-DOC, expressed in terms of death during treatment for 5 consecutive days or significant increases in the parameters 
used to monitor renal and hepatic functions, was 0.8 mg/kg per day. AMB-LIP were the least oxic, the MTD being 11 mg/kg 
per day. The formulation with AMB complexed to DSPG (PEG-AMB-LIP type 1) was as toxic as AMB-DOC. This PEG- 
AMB-LIP formulation was omitted from further studies on biodistribution. With AMB complexed to PEG-DSPE (PEG-AMB- 
LIP type 2) toxicity was substantially reduced, resulting in a MTD of 9 mg/kg per day. Biodistribution of radiolabeled 
PEG-AMB-LIP type 2 was compared with that of AMB-LIP. Blood residence time of PEG-AMB-LIP type 2 was prolonged as 
compared to AMB-LIP; For PEG-AMB-LIP type 2 at 24 h after administration 30% of the injected osage of AMB in intact 
liposomes was circulating versus 6% for AMB-LIP. 
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1. Introduction 
Abbreviations: AMB, amphotericin B; AMB-DOC, amphotericin 
B-deoxycholate; ALAT, alanine aminotransferase; ASAT, aspartate 
aminotransferase; BUN, blood urea nitrogen; CREAT, serum creat- 
inine; DF, deferoxamine m sylate; Chol, cholesterol; DSPG, distea- 
roylphosphatidylglcerol; HSPC, hydrogenated soybean 
phosphatidylcholine; MPS, mononuclear phagocyte system; PEG- 
DSPE, polyethylene glycol(1900) derivatized distearoylphosphati- 
dylethanolamine 
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The therapy of choice for most invasive fungal infec- 
tions remains amphotericin B (AMB),  administered as 
amphotericin-deoxycholate (AMB-DOC or Fungi- 
zone®). However, its clinical use is limited by toxic 
side effects [1 ]. A promising approach in the treatment 
of deep systemic fungal infections is AMB incorpo- 
rated in liposomes or other lipid-carriers [ 1-3 ]. With 
respect to the industrially produced preparations 
AmBisome ®, ABLC (AMB lipid complex) and 
Amphocil ® it is evident that these have quite different 
structural nd pharmacokinetic characteristics [ 4 ]. The 
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relatively large structures of ABLC, as well as the small 
discoidal particles of Amphocil ® are rapidly taken up 
by the mononuclear phagocyte system (MPS), 
whereas mall liposomes as in AmBisome ® remain in 
the circulation for relatively prolonged periods. Until 
now it is not known whether blood residence time is an 
important variable influencing the therapeutic ndex of 
AMB-liposomes. 
The ability to achieve a significantly longer blood 
residence time of liposomes creates new opportunities 
for improving the delivery of antimicrobial gents to 
infected tissues [5,6]. Recently, many reports have 
shown that hydrophilic phosphatidylethanolamine 
derivatives of monomethoxy polyethylene glycols 
(PEG-PE) attached to the liposomes enhance blood 
circulation time without he limitations of lipid dose or 
rigid composition [ 6-19 ]. Such long-circulating lipo- 
somes have been named sterically stabilized liposomes. 
As the effects of inclusion of PEG-DSPE on the 
therapeutic index of AMB-liposomes are not yet 
reported, we have investigated whether long-circulat- 
ing AMB containing liposomes can be prepared by 
incorporation of PEG-DSPE, and whether the incor- 
poration of PEG-DSPE affects the toxicity and biod- 
istribution of the preparation. 
Successful liposomal encapsulation of AMB 
requires that AmB is complexed, e.g. to DSPG, as in 
the current AmBisome ® formulation. We have dem- 
onstrated that complexation ofAMB to PEG-DSPE can 
also be achieved (manuscript in preparation). In this 
study the preparation of two different formulations of 
liposomes containing both PEG-DSPE and AMB is 
described. PEG-AMB-LIP type 1, in which PEG-DSPE 
was added to AMB-liposomes with AMB complexed 
to DSPG, as well as PEG-AMB-LIP type 2, in which 
AMB was complexed to PEG-DSPE and DSPG was 
omitted from the preparation, were prepared. These 
pegylated formulations were compared with non-pegy- 
lated AMB-liposomes (referred to as AMB-LIP) 
regarding toxicity and biodistribution. 
2. Materials and methods 
2.1. Materials 
AMB and AMB-DOC (Fungizone ® for intravenous 
infusion) were kindly provided by Bristol Myers- 
Squibb, The Netherlands. AMB-DOC was reconsti- 
tuted according to the manufacturer's in tructions with 
distilled water to give a standard solution of 5 g AMB / 
1. Lipid powder consisting of HSPC:Chol:DSPG:AMB 
in a molar ratio of 2:1:0.8:0.4 in which AMB is com- 
plexed to DSPG was kindly provided by Vestar Inc. 
(San Dimas, CA). Hydrogenated soybean phosphati- 
dylcholine (HSPC), cholesterol (Chol), monome- 
thoxy polyethylene glycol (1900) succinimidyl 
succinate (activated PEG), distearoylphosphatidyle- 
thanolamine (DSPE), were all kindly provided by Ves- 
tar Inc. Dimethyl sulfoxide (DMSO) was from Janssen 
Chimica (Tilburg, The Netherlands). Deferoxamine 
mesylate (DF) was from CibaGeigy (Basel, Switzer- 
land). 67Ga-citrate was from Nordian (Montreal, 
Canada), ~In-chloride from Frosst (Quebec, 
Canada). Hydroxyquinoline sulfate (oxine) was from 
Sigma (St. Louis, MO). PEG (1900) derivative of 
DSPE (PEG-DSPE) was synthesized as described by 
Blume and Cevc [ 11 ]. 
2.2. Liposome preparation 
Liposome preparations consisted of 
HSPC:Chol:DSPG:AMB in a molar atio of 2:1:0.8:0.4 
(AMB-LIP), HSPC:Chol:DSPG in a molar ratio of 
2:1:0.8 (PLACEBO-LIP), PEG-DSPE:HSPC:Chol: 
DSPG: AMB in a molar atio of 0.29:2:1:0.8:0.4 (PEG- 
AMB-LIP type 1 ), PEG-DSPE:HSPC:Chol:AMB in a 
molar ratio of 0.21 : 1.79:1:0.32 (PEG-AMB-LIP type 
2), and PEG-DSPE:HSPCChol in a molar ratio of 
0.21:1.79:1 (PEG-PLACEBO-LIP type 2). AMB is 
very poorly soluble in chloroform/methanol (1:1, v/ 
v), and therefore as a first step in the preparation of 
AMB containing liposomes AMB was complexed to 
either DSPG (AMB-LIP and PEG-AMB-LIP type 1 ) 
or to PEG-DSPE (PEG-AMB-LIP type 2). For AMB- 
LIP, PLACEBO-LIP, PEG-AMB-LIP type 1, and 
PEG-PLACEBO-LIP type 2 a chloroform/methanol 
(1:1, v/v) solution of lipid powder or lipid mixture 
was evaporated to dryness in a round-bottom flask at 
65°C. For PEG-AMB-LIP type 2, AMB was com- 
plexed to PEG-DSPE by adding small volumes (20- 
50 fd) of 1 N HC1 to a suspension of AMB and PEG- 
DSPE in 2 ml chloroform/methanol (1:1, v/v) ,  fol- 
lowed by heating at 65°C and vortex mixing until the 
solution cleared. Small volumes (10-15 fd) of 1 N 
NaOH were added, followed by addition of HSPC and 
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Chol. When precipitation ofAMB was observed, again 
small volumes of I N HCI were added until the solution 
cleared. This lipid mixture was evaporated to dryness 
in a round-bottom flask at 65°C. The lipid film was 
hydrated by vortex mixing in a buffer solution contain- 
ing 10 mM sodium succinate and 10% (w/v) sucrose 
(pH 5.5) at 65°C. For biodistribution experiments 5 
mM DF was added to this buffer. Liposomes were 
sonicated resulting in an average particle size of 100 
nm (range 95-105 nm), as measured by dynamic light 
scattering (Malvern 4700 system, Malvern, UK). 
Biodistribution of intact liposomes was performed 
using liposomes radiolabeled with 67Ga-DF as 
described by Woodle [20]. The labeling resulted in 
formation of a 67Ga-DF complex in the aqueous interior 
of liposomes. As shown by Gabizon et al. [ 21 ], this 
complex is appropriate for in vivo tracing of intact 
liposomes because of the advantages of minimal trans- 
location of radioactive label to plasma proteins and the 
rapid renal clearance rate when the label is released 
from the liposomes extracellularly. Lipos0mes were 
separated from non-entrapped AMB, DF, or radiolabel 
by gel filtration on a Sephadex G-50 column (Phar- 
macia, Uppsala, Sweden), and concentrated by using 
300 kDa Microsep filters (Filtron, Breda, The Nether- 
lands). Phospholipid concentration was determined by 
a phosphate assay [22]. AMB concentration was deter- 
mined spectrophotometrically at 405 nm, after destruc- 
tion of the liposomes in DMSO/methanol ( 1:1, v/v) .  
MTD was defined as the maximum dosage that did not 
result in death during treatment or more than 3-fold 
increase in the indices for renal and liver function, as 
compared to untreated mice. 
2.4. Biodistribution studies 
Biodistribution of AMB-LIP, PLACEBO-LIP, 
PEG-AMB-LIP type 2 and PEG-PLACEBO-LIP type 
2 was investigated. Radiolabeled liposomes were 
administered i.v. at 85/zmol ipid/kg (equivalent to 9 
mg/kg AMB) as a single dose in uninfected mice. In 
two separate experiments of three mice for each differ- 
ent time interval after injection, 200/xl blood was col- 
lected from the mice in heparinized tubes. Mice were 
killed, and whole organs (liver, spleen, lungs, and kid- 
neys) were excised. Blood and organs, as well as the 
injected dosage of liposomes were counted for 67Ga- 
DF in a gamma counter (Minaxy 5530, Packard Instru- 
ments, Downers Grove, USA). For the AMB 
containing preparations blood or organs from three 
mice were pooled and organs were homogenized in
distilled water. Blood and tissue samples were stored 
at - 80°C until just before HPLC analysis, as described 
before [23]. In a separate xperiment using ~lln- 
labeled red blood cells [24] blood volume was deter- 
mined to be 7.5% of body weight and blood correction 
factors were determined for each organ. 
2.3. Determination ofmaximum tolerated osage 
(MTD) 
Toxicity of AMB-DOC, AMB-LIP, PEG-AMB-LIP 
type 1, and PEG-AMB-LIP type 2 was measured in 
uninfected specific pathogen free female BALB /c mice 
(14-to 20-week-old, 22-27 g lffa Credo, L'Arbresle, 
France). Mice (6 per group) were treated i.v. for 5 
consecutive days with each of the preparations once 
daily (q 24 h) with AMB dosages ranging from 0.1 to 
25 mg/kg per day. Acute mortality was assessed 
directly following injection of the preparation. Blood 
urea nitrogen (BUN) and serum creatinine (CREAT), 
as parameters for renal toxicity, and aspartate amino- 
transferase (ASAT) and alanine aminotransferase 
(ALAT), as parameters for liver toxicity, were deter- 
mined by established methods in serum samples of 
mice killed at 24 h after termination of treatment. The 
3. Results and discussion 
The MTDs in uninfected mice of AMB-DOC, AMB- 
LIP, PEG-AMB-LIP type 1, and PEG-AMB-LIP type 
2 are presented in Table 1. The MTD of AMB-DOC 
in terms of death during treatment was 0.8 mg/kg per 
day. At this dosage renal or liver toxicity was not seen. 
With AMB-LIP (a formulation with a lipid composi- 
tion as in AmBisome ®) the MTD with no death during 
treatment was 19 mg/kg per day. At this dosage renal 
toxicity was not yet observed, whereas the MTD with 
respect to liver toxicity was 11 mg/kg per day. Incor- 
poration of PEG-DSPE resulting in PEG-AMB-LIP 
type 1 led to a preparation that was as toxic as AMB- 
DOC. For PEG-AMB-LIP type 2 death during treat- 
ment was shown at dosages higher than 13 mg/kg per 
day. At this dosage renal toxicity was not seen. For 
liver toxicity the MTD was 9 mg/kg per day. The high 
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Table 1 
Maximum tolerated dosage (MTD) of AMB-DOC, AMB-LIP, PEG-AMB-LIP type 1, and PEG-AMB-LIP type 2 in uninfected mice a
Parameter of toxicity MTD h (mg/kg per day) 
AMB-DOC AMB-LIP  PEG-AMB-LIP type 1 PEG-AMB-LIP type 2 
Death during treatment 0.8 19 0.8 13 
Impaired renal function > 0.8 > 19 > 0.8 > 13 
Impaired liver function > 0.8 11 > 0.8 9 
aMice were treated i.v. for five consecutive days once daily (q 24 h) with AMB-DOC or with sonicated liposomes with an average diameter of
100 nm: AMB-LIP ( HSPC / Chol /DSPG /AMB ), PEG-AMB-LIP type 1 (PEG-DSPE / HSPC / Chol /DSPG /AMB ), or PEG-AMB-LIP type 2 
(PEG-DSPE/HSPC/Chol/AMB). AMB dosages ranged from 0.1 to 1.0 mg/kg per day in steps of 0.1 mg/kg per day, and above 1.0 mg/kg 
per day in steps of 2.0 mg/kg per day. Two experiments of three mice each (n = 6) for each dosage were performed. 
bToxicity was determined in terms of death during treatment, or more than 3-fold increase inthe indices for renal function (BUN and CREAT) 
and liver function (ASAT, ALAT) as compared toplacebo-treated mice, determined at 24 h after termination f treatment. 
toxicity of the PEG-AMB-LIP type 1 preparation is
probably due to a very toxic subpopulation of small 
particles containing AMB. A heterogeneity in particle 
size was observed after ultracentrifugation of the PEG- 
AMB-LIP type 1 preparation at 260 000 × g. It was 
shown by dynamic light scattering measurements that 
particles of approximately 100 nm containing AMB 
were sedimented atthis speed, whereas mall particles 
of approximately 40 nm containing AMB remained in 
the supernatant. There was a marked difference with 
respect o toxicity in terms of acute death in mice 
between the particles of 40 and 100 nm. Acute death 
was observed after i.v. administration f the 40 nm 
AMB-particles at a dosage of 0.6 mg/kg, whereas no 
toxicity was observed with the 100 nm AMB-particles 
at a dosage of 6 mg/kg. As a first step in the preparation 
of PEG-AMB-LIP type 1, AMB is complexed to 
DSPG. This lipophilic AMB-DSPG complex is 
inserted in the phospholipid bilayer during spray-dry- 
ing and thus helps to retain AMB in the liposome. PEG- 
DSPE is added to this formulation in which AMB is 
already complexed to DSPG. It is conceivable that 
competition between PEG-DSPE and DSPG for com- 
plexation of AMB occurred, resulting in the formation 
of highly toxic AMB-containing lipid particles of 40 
nm beside less toxic 100 nm AMB-liposomes. In PEG- 
AMB-LIP type 2 in which DSPG was omitted from the 
preparation, AMB was complexed to PEG-DSPE. 
PEG-AMB-LIP type 2 did not show the heterogeneity 
in particle size, and this was also not observed for 
AMB-LIP. As the PEG-AMB-LIP type 1 preparation 
was very toxic, these liposomes were omitted from 
further studies on biodistribution that were performed 
with AMB-LIP and PEG-AMB-LIP type 2. 
Biodistribution studies were performed with 67Ga- 
DF labeled liposomes. 67Ga-DF was used as marker for 
intact liposomes. In studies with AMB-containing lipo- 
somes both 67Ga-DF levels as well as AMB concentra- 
tions were determined. For both AMB-LIP as well as 
PEG-AMB-LIP type 2, AMB levels as percentage of
injected osage in blood and liver + spleen were equiv- 
alent o levels of intact liposomes (Fig. 1 and Fig. 2), 
suggesting that AMB levels primarily represent lipo- 
some-associated AMB. For both AMB-LIP and PEG- 
AMB-LIP type 2 levels in kidney and lung never 
exceeded 3 % and 1% of injected liposome dose, respec- 
tively (data not shown). Comparison of the blood res- 
idence of AMB-LIP versus PLACEBO-LIP shows that 
the presence of AMB in the liposome preparation 
induced a dramatic drop in blood level of intact lipo- 
somes within 5 min after administration (Fig. 1 ). As 
this initial drop is seen in both the 67Ga-DF marker as 
well as in AMB concentration (Fig. 1 ) it is unlikely 
that this initial decrease is due to leakage of 67Ga-DF 
or AMB. Although the initial hepatosplenic uptake of 
AMB-LIP within 5 min after administration is high 
( 29% of injected osage), this can still not account for 
the low blood level (47% of injected osage) at this 
time point. As the exact localization of the distributed 
liposomes in other organs, such as bone marrow, brain, 
muscle, and skin at 5 min after administration was not 
determined, the rapid elimination ofAMB-LIP is unex- 
plained. After this initial drop in blood level of lipo- 
somal AMB a relatively prolonged blood residence 
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Fig. 1. Biodistribution of 67Ga-DF labeled liposomes at various intervals after i.v. injection. Sonicated liposomes with an average diameter of 
100 nm were injected intravenously in mice at a dosage of 85 /xmol lipid/kg. (O) PLACEBO-LIP: HSPC/Chol/DSPG; (0 )  AMB-LIP: 
HSPC/Chol/DSPG/AMB. Data are expressed as percentage of injected dosage cpm 67Ga-DF (solid line) as mean 5: S.D. for two separate 
experiments of three mice each (n = 6), or as percentage of injected dosage AMB (broken line) as mean + range for two separate experiments 
with in each experiment blood or tissue from three mice pooled. Where no error-bars are seen the range is smaller than the data points. 
time was observed with 6% of injected dosage circu- 
lating at 24 h after administration. In line with expec- 
tations, it was shown that inclusion of PEG-DSPE into 
PEG-AMB-LIP type 2 resulted in a prolonged blood 
residence time of liposomal AMB as compared to 
AMB-LIP. Unfortunately, due to problems with respect 
to aggregation of liposomes during preparation, it was 
not possible to compare PEG-AMB-LIP type 2 with its 
appropriate control, i.e. non-pegylated AMB-lipo- 
somes with omission of not only PEG-DSPE but also 
DSPG. Successful liposomal encapsulation of AMB 
requires that AMB is complexed to either DSPG, as in 
AMB-LIP, or to PEG-DSPE, as in PEG-AMB-LIP type 
2. An effect of AMB on blood residence time of the 
pegylated liposomes was not observed with PEG- 
AMB-LIP type 2 (Fig. 2). Both PEG-PLACEBO-LIP 
type 2 as well as PEG-AMB-LIP type 2 showed a long 
blood residence time with 20-30% of the injected os- 
age of liposomes till circulating at 24 h after admin- 
istration. These results are in good agreement with 
those reported elsewhere for PEG-liposomes with sim- 
ilar particle size [6-8,18]. However, in the present 
study a relatively high hepatosplenic uptake of the lipo- 
somes of 34-43% was observed at 24 h after adminis- 
tration, as compared to the other studies [6-8,18] in 
which the hepatosplenic uptake ranged from 7 to 28% 
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Fig. 2. Biodistribution of 67Ga-DF labeled liposomes at various intervals after i.v. injection. Sonicated liposomes with an average diameter of 
100 nm were injected intravenously in mice at a dosage of 85/xmol lipid/kg. ([]) PEG-PLACEBO-LIP type 2: PEG-DSPE/HSPC/Chol; (• )  
PEG-AMB-LIP type 2: PEG-DSPE/HSPC/Chol/AMB. Data are expressed as percentage of injected dosage cpm 67Ga-DF (solid line) as 
mean + S.D. for two separate experiments of three mice each (n = 6), or as percentage of injected dosage AMB ( broken line) as mean + range 
for two separate experiments with in each experiment blood or tissue from three mice pooled. Where no error-bars are seen the range is smaller 
than the data points. 
at 24 h after i.v. administration. This might be related 
to differences in size distribution of the liposomes dis- 
persion, as different methods for liposome sizing were 
used (sonication in the present study versus extrusion 
in the other studies). It is possible that sonication, as 
compared to the extrusion method, yields a preparation 
with relatively increased numbers of liposomes smaller 
than 100 nm. Extravascular localization of these small 
liposomes after passage through the fenestrated vas- 
cular endothelial lining of the liver sinusoids may 
occur. In conclusion, incorporation of PEG-DSPE in 
AMB-LIP with AMB complexed to DSPG (PEG- 
AMB-LIP type 1) results in an extremely toxic 
preparation. When AMB is complexed to PEG-DSPE 
and DSPG is omitted from the preparation (PEG- 
AMB-LIP type 2) toxicity is substantially reduced. In 
comparison with AMB-LIP this PEG-AMB-LIP type 
2 preparation shows a slightly increased toxicity. Blood 
residence time of liposomal AMB is prolonged with 
PEG-AMB-LIP type 2 as compared to AMB-LIP. To 
what extent he increased toxicity as well as prolonged 
blood residence time of liposomal AMB with PEG- 
AMB-LIP type 2 are determining factors with respect 
to improved efficacy as compared to AMB-LIP in the 
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treatment of fungal infections is now under investiga- 
tion. 
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